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Summary
Background The risk of individuals having adverse eﬀ ects from drug use (eg, alcohol) generally depends on the 
frequency of use and potency of the drug used. We aimed to investigate how frequent use of skunk-like (high-potency) 
cannabis in south London aﬀ ected the association between cannabis and psychotic disorders.
Methods We applied adjusted logistic regression models to data from patients aged 18–65 years presenting to South 
London and Maudsley NHS Foundation Trust with ﬁ rst-episode psychosis and population controls recruited from the 
same area of south London (UK) to estimate the eﬀ ect of the frequency of use, and type of cannabis used on the risk 
of psychotic disorders. We then calculated the proportion of new cases of psychosis attributable to diﬀ erent types of 
cannabis use in south London.
Findings Between May 1, 2005, and May 31, 2011, we obtained data from 410 patients with ﬁ rst-episode psychosis and 
370 population controls. The risk of individuals having a psychotic disorder showed a roughly three-times increase in 
users of skunk-like cannabis compared with those who never used cannabis (adjusted odds ratio [OR] 2·92, 95% CI 
1·52–3·45, p=0·001). Use of skunk-like cannabis every day conferred the highest risk of psychotic disorders compared 
with no use of cannabis (adjusted OR 5·4, 95% CI 2·81–11·31, p=0·002). The population attributable fraction of ﬁ rst-
episode psychosis for skunk use for our geographical area was 24% (95% CI 17–31), possibly because of the high 
prevalence of use of high-potency cannabis (218 [53%] of 410 patients) in our study.
Interpretation The ready availability of high potency cannabis in south London might have resulted in a greater 
proportion of ﬁ rst onset psychosis cases being attributed to cannabis use than in previous studies.
Funding UK National Institute of Health Research (NIHR) Specialist Biomedical Research Centre for Mental Health, 
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Introduction
Cannabis is the most popular illicit drug in the world. 
Uruguay was the ﬁ rst country to legalise its use and 
several US states have done so or are in the process of 
doing similar.1 Therefore, any harm caused by cannabis 
use should be quantiﬁ ed. Prospective epidemiological 
studies have consistently reported that use of cannabis 
increases the risk of schizophrenia-like psychosis.2,3 In 
the UK, the investigators of the 2012 Schizophrenia 
Commission4 concluded that cannabis use is the most 
preventable risk factor for psychosis, and research that 
aims to improve estimation of the drug’s contribution to 
illness development should be pursued.
The aspects of exposure to cannabis (eg, age at ﬁ rst 
use, frequency of use, duration of use) that confer the 
greatest eﬀ ect on risk of psychosis are unclear. Such 
information would be valuable for public education 
and to estimate the proportion of psychosis cases that 
could be prevented if harmful patterns of cannabis use 
were removed from the population. The few studies5,6 
that have tried to estimate the eﬀ ect of cannabis use 
on the number of new cases of psychosis in speciﬁ c 
populations have been limited by the scarcity of 
accurate information on patterns of cannabis use.
The risk of adverse eﬀ ects for mental health and 
cognition posed by cannabis use has been suggested to 
depend on the potency of the type of cannabis used.7 For 
example, in a previous study8 of part of the population 
reported here, we noted that skunk-like types of 
cannabis, which contain very high concentrations of 
Δ-9-tetrahydrocannabinol (THC), seemed to have a 
greater psychotogenic eﬀ ect than did hash (resin), 
which is known to contain much less THC.
We analysed detailed data for history of cannabis use, 
aiming to: compare the patterns and types of cannabis 
used between patients with ﬁ rst-episode psychosis and a 
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population control sample; use the data for pattern of 
cannabis use to develop a cannabis exposure measure 
that accurately estimates the risk of psychotic disorders; 
and calculate the proportion of cases of psychosis in our 
study area attributable to use of cannabis, particularly 
high-potency cannabis, if we assumed causality.
Methods
Study design and participants
As part of the GAP study,8 we did a case-control study at 
the inpatient units of the South London and Maudsley 
(SLaM) NHS Foundation Trust. We approached all patients 
aged 18–65 years who presented with ﬁ rst-episode 
psychosis. We invited patients to participate if they met the 
International Classiﬁ cation of Diseases 10 criteria for a 
diagnosis of non-aﬀ ective (F20–F29) or aﬀ ective (F30–F33) 
psychosis, validated by administration of the Schedules for 
Clinical Assessment in Neuropsychiatry (SCAN).9 We 
excluded individuals who met the criteria for organic 
psychosis (F09). If patients were too unwell to cooperate, 
we re-contacted them after the start of treatment.
We recruited controls using internet and newspaper 
advertisements and by distributing leaﬂ ets at train stations, 
shops, and job centres. None of the advertising material 
mentioned cannabis or illicit drug use. Volunteers were 
administered the Psychosis Screening Questionnaire10 and 
were excluded if they met the criteria for a psychotic disorder 
or if they reported a previous diagnosis of psychotic illness. 
This study is part of the GAP study, which was granted 
ethical approval by SLaM and Institute of Psychiatry Local 
Research Ethics Committee. All case and control individuals 
included in the study gave written informed consent.
Procedures
We obtained sociodemographic data using the Medical 
Research Council Schedule.11 From March, 2006, we took 
a more detailed history of cannabis use by adding the 
Cannabis Experience Questionnaire modiﬁ ed version 
(CEQmv) to the assessment.8,12 From the CEQmv, we derived 
information on history of use of tobacco, alcohol, other 
recreational drugs, and detailed information on cannabis 
use (age at ﬁ rst use, duration of use, frequency of use, 
type used).
Measures of cannabis use relevant to the analysis were: 
lifetime history of cannabis use—ie, had the individual 
ever used cannabis at any point in their life (no scores 0, 
yes scores 1); lifetime frequency of cannabis use—ie, the 
frequency that characterised the individual’s most 
consistent pattern of use (none scores 0, less than once per 
week every week scores 1, at weekends scores 2, every day 
scores 3); and type of cannabis used—ie, the type most 
used by the subject (none scores 0, low potency [hash-type] 
scores 1, high potency [skunk-type] scores 2). This variable 
was grouped in accordance with the characteristics of the 
cannabis samples seized by the Metropolitan Police in 
London, as reported by Potter and colleagues13 and the 
Home Oﬃ  ce study (appendix).14 Finally, we used a 
seven-item composite cannabis exposure measure derived 
from the lifetime frequency of use and the most used type 
(none scores 0, hash less than once per week every week 
scores 1, hash at weekends scores 2, hash every day 
scores 3, skunk less than once per week scores 4, skunk at 
weekends scores 5, skunk every day scores 6) to investigate 
which patterns of use conferred the greatest risk.
Statistical analysis
We analysed data using Stata 13. We used χ² tests and 
t tests (or Mann-Whitney U tests) to test for associations 
between potential confounding variables and between 
presence of psychotic disorder and exposure to cannabis 
use. We also used these tests to establish whether missing 
data for the cannabis use exposure were associated with 
case-control status and therefore likely to bias the results.
We used logistic regression to analyse whether 
individual indicators of cannabis use (lifetime use, age at 
ﬁ rst use, duration and frequency of use, and most used 
type of cannabis) improved estimation of the likelihood 
of psychotic disorders (ie, case status), in comparisons of 
cannabis users with non-users.
We used the punafcc command in Stata 13 to estimate 
the population attributable fraction (PAF), with conﬁ dence 
intervals, for each cannabis use variable. The PAF 
measures the population eﬀ ect of an exposure by providing 
an estimate of the proportion of disorder that would be 
prevented if the exposure were removed. However, 
causality does not have to be proven before the PAF can be 
estimated, and this causation is not usually established 
when PAFs are estimated (indeed no single study could 
ever prove causation). Because the same proportion of 
disorder attributable to a speciﬁ c risk factor can also be 
attributable to other factors with which the speciﬁ c risk 
factor might interact, PAFs for multiple risk factors can 
add up to more than 100%. Furthermore, the PAF depends 
on both the prevalence of exposure (ie, measures of 
cannabis use) in cases and the odds ratio (OR) for the 
exposure, such that a risk factor with a modest OR can 
have a major population eﬀ ect if the factor is common.
Role of the funding source
All funders contributed to data collection by providing 
the salaries of the research workers collecting the data. 
The funders of the study had no role in study design, 
data analysis, data interpretation, or writing of the report. 
All authors had full access to all the data in the study and 
had ﬁ nal responsibility for the decision to submit for 
publication.
Results
Between May 1, 2005, and May 31, 2011, we approached 
606 patients with ﬁ rst-episode psychosis. Of these 
606 patients, 145 (24%) refused to participate. Thus, we 
recruited 461 patients with ﬁ rst-episode psychosis. Patients 
who refused to participate were more likely to be men 
(p<0·004) and of Black Caribbean and Black African ethnic See Online for appendix
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origin (p=0·001) than were those who consented. 
Therefore, in all the analyses, we tested for the potential 
confounding eﬀ ects of ethnic origin and gender. During 
the same period and from the geographical area served by 
the clinical units, we recruited 389 control individuals, 
aged 18–65 years, who were similar to the local population 
in terms of ethnic origin, education, and employment 
status (table 1). The later addition of CEQmv meant that 
there were data missing on detailed patterns of cannabis 
use for those participants recruited early in the project. 
The data we present here are therefore based on 410 (89%) 
of 461 patients with ﬁ rst-episode psychosis and 370 (95%) 
of 389 controls for whom we had data for cannabis use.
The patients with ﬁ rst-episode psychosis consisted of 
more men and were younger than the control group 
(table 1). As noted previously,15 patients with ﬁ rst-episode 
psychosis were also more likely to be of Black ethnic 
origin (Caribbean or African) compared with controls, 
and less likely to have completed a high level of education 
than were controls (table 1).
A larger proportion of patients with ﬁ rst-episode 
psychosis (184 [45%] of 410 individuals) reported having 
smoked 100 tobacco cigarettes or more than did controls 
(60 [16%] of 370 individuals; p<0·0001), but the groups did 
not diﬀ er in lifetime history of other substance use 
(p=0·615), or alcohol units consumed per week (p=0·083). 
Patients with ﬁ rst-episode psychosis were no more likely 
than were controls to report a lifetime history of ever 
having used cannabis, but were more likely to use 
cannabis every day and to mostly use high-potency 
(skunk-like) cannabis (table 2). A small proportion of 
cannabis users (3 [0·6%] of 507 individuals) reported 
having used cannabis more than four days a week and 
they were included in the every day category.
Among cannabis users, the mean duration of use did not 
diﬀ er between patients with ﬁ rst-episode psychosis and 
controls (table 2). On average, both groups started using 
cannabis in their mid-teens, although distribution of the 
age at ﬁ rst cannabis use seemed to be skewed (mean 
16·1 years, SD 4·2, median 16 years in the patients with 
ﬁ rst-episode psychosis vs mean 16·6 years, SD 3·2, median 
17 years in the control group; Z=2·88; p=0·146). Patients 
with ﬁ rst-episode psychosis were more likely to start using 
cannabis at age 15 years or younger than were controls.
When we combined data on frequency of cannabis use 
and most used type into a single variable, the composite 
cannabis exposure measure, controls were more likely to 
be occasional users of low-potency cannabis (hash), and 
patients with ﬁ rst-episode psychosis were more likely to 
be daily users of high-potency cannabis (skunk; ﬁ gure 1; 
p<0·0001).
A logistic regression, adjusted for age, gender, ethnic 
origin, number of cigarettes smoked, alcohol units and 
lifetime use of other illicit drugs, education, and 
employment history, showed that individuals who had ever 
used cannabis were not at increased risk of psychotic 
disorder compared with those who had never used 
For more on demographic 
composition of the local 
population see www.statistics.
gov.uk/census
First-episode 
psychosis 
group 
(n=410)
Control 
group 
(n=370)
p value
Age, years 27·1 (8·7) 30·0 (9·0) 0·0001
Gender ·· ·· 0·004
Male 271 (66%) 209 (56%) ··
Female 139 (34%) 161 (44%) ··
Ethnic origin ·· ·· 0·0001
White 132 (32%) 212 (57%) ··
Black Caribbean 136 (33%) 73 (20%) ··
Black African 98 (24%) 38 (10%) ··
Asian/other 44 (11%) 47 (13%) ··
Education ·· ·· 0·0003
No qualiﬁ cation 60 (15%) 8 (2%) ··
GCSEs 116 (28%) 31 (8%) ··
A levels or vocational training 153 (37%) 151 (41%) ··
University 81 (20%) 180 (49%) ··
Ever employed ·· ·· 0·001
Yes 361 (88%) 353 (95%) ··
No 46 (11%) 15 (4%) ··
No details 3 (1%) 2 (1%) ··
Data are mean (SD) or n (%) unless stated otherwise. 
 Table 1: Population sociodemographics
First-episode 
psychosis 
group 
(n=410)
Control 
group 
(n=370)
p value
Total population
Lifetime history of cannabis use ·· ·· 0·277
Yes 275 (67%) 232 (63%) ··
No (never used) 135 (33%) 138 (37%) ··
Frequency of use ·· ·· <0·0001
Less than once per week 68 (17%) 128 (35%) ··
At weekends 84 (20%) 63 (17%) ··
Every day 123 (30%) 41 (11%) ··
Most used type of cannabis ·· ·· <0·0001
Never used 135 (33%) 138 (37%) ··
Hash-like 57 (14%) 162 (44%) ··
Skunk-like 218 (53%) 70 (19%) ··
Cannabis users
Duration of use (years) 9·7 (7·4) 9·1 (7·8) 0·635
No details 3 1 ··
Age at ﬁ rst cannabis use (years) 16·1 (4·2) 16·6 (3·2) 0·146
No details 3 1 ··
Age at ﬁ rst use ≤15 years ·· ·· 0·028
No 172 (63%) 178 (77%) ··
Yes 100 (36%) 53 (23%) ··
No details 3 1 ··
Data are n (%) or mean (SD) unless stated otherwise. 
 Table 2: Cannabis use
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cannabis (n=775 [data for employment history was missing 
for ﬁ ve participants, OR 0·93, 95% CI 0·67–1·52, 
p=0·569). Individuals who started using cannabis at ages 
younger than 15 years had modestly, but signiﬁ cantly, 
increased risk of psychotic disorders compared with those 
who never used cannabis (table 3). People who used 
cannabis or skunk every day were both roughly three times 
more likely to have a diagnosis of a psychotic disorder than 
were those who never used cannabis (table 3).
We used logistic regression (n=775) to test whether the 
composite cannabis exposure measure predicted risk of 
psychotic disorder more accurately than the individual 
markers, frequency of cannabis use and most used type 
of cannabis, alone. Individuals who mostly used low-
potency (hash-like) cannabis occasionally (p=0·493), at 
weekends (p=0·102), or daily (p=0·626) had no increased 
likelihood of psychotic disorders compared with those 
who never used cannabis (ﬁ gure 2).
Compared with those who never used cannabis, 
individuals who mostly used skunk-like cannabis were 
nearly twice as likely to be diagnosed with a psychotic 
disorder if they used it less than once per week (p=0·020), 
almost three times as likely if they used it at weekends 
(p=0·008), and more than ﬁ ve times as likely if they were 
daily users (p=0·001; ﬁ gure 2).
Based on the estimated adjusted OR for daily cannabis 
use (3·04, 95% CI 1·91–7·76), we calculated that, if we 
assumed causality, 19·3% (13·1–27·0) of psychotic 
disorders in the study population were attributable to 
exposure to daily cannabis use. The PAF of psychotic 
disorders in the study population that were attributable to 
high potency cannabis use was 24·0% (17·4–30·6) and the 
PAF for the two exposures combined, skunk use every day, 
was 16·0% (14·0–20·3; table 4). If causality is assumed, 
this ﬁ nding suggests that skunk alone was responsible for 
the largest proportion of new cases (24%) of psychotic 
disorder in the study population, an eﬀ ect driven by its 
high prevalence among patients with ﬁ rst-episode 
psychosis who used cannabis (218 [53%] of 410 patients).
Discussion
The results of our study support our previous conclusions 
from analysis of part of the sample;8 use of high-potency 
cannabis (skunk) confers an increased risk of psychosis 
compared with traditional low-potency cannabis (hash). 
Additionally, because of the increased sample size in the 
present study, we were able to combine information on 
frequency of use and type of cannabis used into a single 
measure. This combined measure suggested that the 
strongest predictor of case-control status (ie, predictor of 
whether a random individual would be case or control) 
was daily-skunk use. Figure 2, which shows the adjusted 
ORs for psychotic disorders for each of the composite 
cannabis exposure measure groups, shows how the ORs 
for skunk users increase with the frequency of use.
Samples of skunk seized in the London area in 2005,13 
2008,14 and more recently, as reported by Freeman and 
colleagues,16 contained more THC than did samples of 
hash, and virtually no cannabidiol. Use of cannabis with a 
high concentration of THC might have a more detrimental 
eﬀ ect on mental health than use of a weaker form. Indeed, 
in line with epidemiological evidence,2,3 the results of 
experimental studies17,18 that investigated the acute eﬀ ects of 
intravenous administration of THC in non-psychotic 
volunteers showed that the resulting psychotic symptoms 
were dependent on the dose. Furthermore, the scarcity of 
cannabidiol in skunk-like cannabis might also be relevant 
because evidence suggests that cannabidiol ameliorates the 
psychotogenic eﬀ ect of THC and might even have 
antipsychotic properties.19,20 The presence of cannabidiol 
might explain our results, which showed that hash users do 
not have any increase in risk of psychotic disorders 
compared with non-users, irrespective of their frequency of 
use. Morgan and colleagues21 previously reported that, in 
healthy volunteers who smoked cannabis, individuals with 
Skunk every day
Skunk at weekends
Skunk less than once per week
Hash every day
Hash at weekends
Hash less than once per week
Never used cannabis
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e
Proportion of individuals (%)
0 10 20 30 40
Patients with first-episode psychosis (n=410)
Controls (n=370)
25% (n=103)
9% (n=32)
17% (n=70)
10% (n=37)
11% (n=46)
10% (n=37) 
5% (n=22)
7% (n=27) 
4% (n=14)
10% (n=35)
5% (n=20)
18% (n=65)
33% (n=135)
37% (n=137)
Odds ratio* (95% CI) p value
Age at ﬁ rst use, years
Never used 1 ··
≥15 years 0·68 (0·34–1·37) 0·292
<15 years 1·55 (1·00–1·39) 0·048
Frequency of use
Never used 1 ··
Less than once per week 0·58 (0·25–1·32) 0·198
Weekends 1·04 (0·41–1·62) 0·929
Every day 3·04 (1·91–7·76) 0·020
Most used type
Never used 1 ··
Hash-like 0·83 (0·52–1·77) 0·903
Skunk-like 2·91 (1·52–3·60) 0·001
*Adjusted for age, gender, ethnic origin, number of cigarettes, alcohol units, 
other drugs used, education, and employment status.
Table 3: Risk for ﬁ rst-episode psychosis for each measure of cannabis 
exposure
Figure 1: Patterns of cannabis use between patients with ﬁ rst-episode psychosis and population controls
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hair traces of THC and cannabidiol had fewer schizophrenia-
like symptoms than those with hair traces of THC only.
In our results, a combined measure of exposure to 
cannabis, daily use of high-potency cannabis, predicted a 
greater risk of psychotic disorders than did the single 
measures of either frequency or potency. However, a 
simple yes-or-no question of whether people use skunk 
might be more useful to identify those at increased risk 
to develop psychosis because of their cannabis use. In 
view of the high prevalence of skunk use in our study 
population, if a causal role for cannabis is assumed, 
skunk use alone was responsible for 24% of those adults 
presenting with ﬁ rst-episode psychosis to the psychiatric 
services in south London.
South London has one of the highest recorded incidence 
rates of psychosis in the UK.22 Boydell and colleagues23 
showed that the incidence of schizophrenia had doubled 
since 1965,24 and that one possible contribution to this was 
the increase in cannabis use among individuals who 
developed schizophrenia. In the present study, we 
identiﬁ ed an increased estimate for the PAF accounted for 
by cannabis (24%) compared with previous studies, which 
reported PAFs of 6·2% in Germany,25 8% in New Zealand,26 
and 13·3% in Holland.5 This ﬁ nding could be caused by, 
not only the greater use of cannabis, but also the greater 
use of high-potency (skunk-like) cannabis in south London 
than in these other countries in earlier periods.27
Hickman and colleagues6 suggested that the number of 
people who need to be treated to stop their cannabis use 
to prevent one case of schizophrenia is large, but would 
become substantially lower if more was understood about 
which individuals are at greatest risk because of their 
pattern of use or their susceptibility to psychosis.6 In 
relation to susceptibility to schizophrenia, Henquet and 
colleagues25 calculated that the PAF for individuals in the 
general population with a predisposition for psychosis at 
baseline was more than double (14·2%) that of the total 
population (6·2%). Our data suggest that the potency of 
the cannabis used also needs to be taken into account in 
calculations of the PAF.
The strategy we used for control recruitment, based on 
a variety of advertising strategies rather than on random 
selection, might have biased the ﬁ ndings. However, the 
ﬁ nal sample of controls was similar, according to the last 
UK census data, to the population from which the cases 
were drawn. Moreover, rather than this approach 
undersampling individuals who used cannabis, the 
proportion of controls with a history of cannabis use 
(63%) was more than the national average (40%) for 
similar age groups,28 showing the high prevalence of 
cannabis use in south London. Furthermore, if we had 
oversampled individuals who used cannabis, this 
oversampling would have caused underestimation of the 
eﬀ ects of cannabis use on risk of psychotic disorders.
A theoretical explanation of why skunk might have been 
preferred by patients with ﬁ rst-episode psychosis is that, 
when they began to experience their illness prodrome, these 
individuals might have sought increased concentrations of 
THC to self-medicate. However, experimental studies show 
that THC induces psychotic symptoms, while cannabidiol 
ameliorates them and reduces anxiety.16–19 That people who 
already have prodromal symptoms would choose a type of 
cannabis that is high in THC and has little cannabidiol 
(such as skunk), which might exacerbate their symptoms, 
rather than a cannabidiol-containing type (such as hash), 
would seem counterintuitive.
A possible limitation of our study is the absence of data 
on number of joints or grams used per day. However, 
because we collected information about use over a period 
of years and not about present use, the reliability of such 
detailed information would probably have been 
confounded by recall bias to a greater extent than was the 
general description of pattern of use that we obtained. The 
fact that we were able to collect detailed information on 
other environmental factors and control for their potential 
confounding eﬀ ects is a key strength of our study.
Our ﬁ ndings show the importance of raising public 
awareness of the risk associated with use of high-potency 
cannabis (panel), especially when such varieties of 
cannabis are becoming more available.29 The worldwide 
Figure 2: Probability of individuals having a psychotic disorder by pattern of cannabis use
OR adjusted for age, gender, ethnic origin, education, employment status, and tobacco use. OR=odds ratio. *p<0·05.
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2·70*
5·40*
Odds ratio*
(95% CI)
Prevalence of exposure 
in patients with ﬁ rst-
episode psychosis
Population 
attributable fraction 
(95% CI)
Daily cannabis use 3·04 (1·91–7·76) 123/410 (30%) 19·3% (13·1–27·0)
Skunk use 2·91 (1·52–3·60) 218/410 (53%) 24·0% (17·4–30·6)
Skunk use every day 5·40 (2·80–11·30) 103/410 (25%) 16·0% (14·0–20·3)
*Adjusted for age, gender, ethnic origin, number of cigarettes, alcohol units, other drugs used, level of education, and 
employment status.
Table 4: Population attributable fraction for daily use of cannabis, skunk use, and skunk use every day
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trend of liberalisation of the legal constraints on the use of 
cannabis further emphasises the urgent need to develop 
public education to inform young people about the risks 
of high-potency cannabis.
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Panel: Research in context
Systematic review
We searched PubMed for studies that estimated the eﬀ ect of cannabis use on the 
number of new cases of psychosis arising in speciﬁ c populations, using both the terms 
“population attributable fraction”, and “number needed to treat”. We also searched for 
studies that investigated the association between the “high potency and/or skunk” 
type of cannabis and psychosis. We included all studies available on PubMed until 
Sept 31, 2014. We identiﬁ ed three studies,7,8.16 all of which met our inclusion criteria.
Interpretation
The association between cannabis use and increased risk of developing schizophrenia-like 
psychosis has been consistently reported by prospective epidemiological studies.2,3 Our 
previous study was the ﬁ rst to show that use of high-potency (skunk-like) cannabis carries 
the highest risk for psychotic disorders.8 In the present larger sample analysis, we replicated 
our previous report and showed that the highest probability to suﬀ er a psychotic disorder is 
in those who are daily users of high potency cannabis. Indeed, skunk use appears to 
contribute to 24% of cases of ﬁ rst episode psychosis in south London. Our ﬁ ndings show the 
importance of raising awareness among young people of the risks associated with the use of 
high-potency cannabis. The need for such public education is emphasised by the worldwide 
trend of liberalisation of the legal constraints on cannabis and the fact that high potency 
varieties are becoming much more widely available. Finally, in both primary care and mental 
health services, a simple yes-or-no question of whether people use skunk might be more 
useful to identify those at increased risk to develop psychosis because of their cannabis use.
